Ebanga™: The most recent FDA-approved drug for treating Ebola
Ebolavirus (EBOV) is a virulent pathogen that causes Ebola virus disease (EVD), which is a life-threatening human condition with a fatality rate of up to 90%. Since the first outbreak in Africa in 1976, several outbreaks and epidemics of EBOV have occurred across the globe. While EVD is recognized a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1083429/full |
| _version_ | 1811158367209521152 |
|---|---|
| author | Elahe Taki Roya Ghanavati Tahereh Navidifar Shirin Dashtbin Shirin Dashtbin Mohsen Heidary Mohsen Heidary Marjan Moghadamnia |
| author_facet | Elahe Taki Roya Ghanavati Tahereh Navidifar Shirin Dashtbin Shirin Dashtbin Mohsen Heidary Mohsen Heidary Marjan Moghadamnia |
| author_sort | Elahe Taki |
| collection | DOAJ |
| description | Ebolavirus (EBOV) is a virulent pathogen that causes Ebola virus disease (EVD), which is a life-threatening human condition with a fatality rate of up to 90%. Since the first outbreak in Africa in 1976, several outbreaks and epidemics of EBOV have occurred across the globe. While EVD is recognized as a serious threat to human health and outbreaks occur almost every year, the treatment options for the disease are limited. In designing therapeutic strategies against EBOV infection, viral structural proteins, such as glycoprotein (GP), could be an excellent target for neutralizing the virus. According to the latest research, GP-specific antibodies are the most efficient post-exposure treatments for EVD. Ansuvimab-zykl, i.e., mAb114 (Ebanga™), is a recent FDA-approved human immunoglobulin monoclonal antibody targeting EBOV GP. This review provides a brief overview of the pharmacological effects and safety profile of ansuvimab in clinical trials and provides insights into the precise mechanism of this new drug for treating EVD. |
| first_indexed | 2024-04-10T05:23:25Z |
| format | Article |
| id | doaj.art-4065513a153c4ec0989990fb0a8d96a9 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-10T05:23:25Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-4065513a153c4ec0989990fb0a8d96a92023-03-08T04:48:35ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-03-011410.3389/fphar.2023.10834291083429Ebanga™: The most recent FDA-approved drug for treating EbolaElahe Taki0Roya Ghanavati1Tahereh Navidifar2Shirin Dashtbin3Shirin Dashtbin4Mohsen Heidary5Mohsen Heidary6Marjan Moghadamnia7Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, IranBehbahan Faculty of Medical Sciences, Behbahan, IranDepartment of Basic Sciences, Shoushtar Faculty of Medical Sciences, Shoushtar, IranDepartment of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, IranMicrobial Biotechnology Research Center, Iran University of Medical Sciences, Tehran, IranDepartment of Laboratory Sciences, School of Paramedical Sciences, Sabzevar University of Medical Sciences, Sabzevar, IranLeishmaniasis Research Center, Sabzevar University of Medical Sciences, Sabzevar, IranDepartment of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, IranEbolavirus (EBOV) is a virulent pathogen that causes Ebola virus disease (EVD), which is a life-threatening human condition with a fatality rate of up to 90%. Since the first outbreak in Africa in 1976, several outbreaks and epidemics of EBOV have occurred across the globe. While EVD is recognized as a serious threat to human health and outbreaks occur almost every year, the treatment options for the disease are limited. In designing therapeutic strategies against EBOV infection, viral structural proteins, such as glycoprotein (GP), could be an excellent target for neutralizing the virus. According to the latest research, GP-specific antibodies are the most efficient post-exposure treatments for EVD. Ansuvimab-zykl, i.e., mAb114 (Ebanga™), is a recent FDA-approved human immunoglobulin monoclonal antibody targeting EBOV GP. This review provides a brief overview of the pharmacological effects and safety profile of ansuvimab in clinical trials and provides insights into the precise mechanism of this new drug for treating EVD.https://www.frontiersin.org/articles/10.3389/fphar.2023.1083429/fullEbola virustreatmentmonoclonal antibodyansuvimab-zyklmAb114EbangaTM |
| spellingShingle | Elahe Taki Roya Ghanavati Tahereh Navidifar Shirin Dashtbin Shirin Dashtbin Mohsen Heidary Mohsen Heidary Marjan Moghadamnia Ebanga™: The most recent FDA-approved drug for treating Ebola Frontiers in Pharmacology Ebola virus treatment monoclonal antibody ansuvimab-zykl mAb114 EbangaTM |
| title | Ebanga™: The most recent FDA-approved drug for treating Ebola |
| title_full | Ebanga™: The most recent FDA-approved drug for treating Ebola |
| title_fullStr | Ebanga™: The most recent FDA-approved drug for treating Ebola |
| title_full_unstemmed | Ebanga™: The most recent FDA-approved drug for treating Ebola |
| title_short | Ebanga™: The most recent FDA-approved drug for treating Ebola |
| title_sort | ebanga™ the most recent fda approved drug for treating ebola |
| topic | Ebola virus treatment monoclonal antibody ansuvimab-zykl mAb114 EbangaTM |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1083429/full |
| work_keys_str_mv | AT elahetaki ebangathemostrecentfdaapproveddrugfortreatingebola AT royaghanavati ebangathemostrecentfdaapproveddrugfortreatingebola AT taherehnavidifar ebangathemostrecentfdaapproveddrugfortreatingebola AT shirindashtbin ebangathemostrecentfdaapproveddrugfortreatingebola AT shirindashtbin ebangathemostrecentfdaapproveddrugfortreatingebola AT mohsenheidary ebangathemostrecentfdaapproveddrugfortreatingebola AT mohsenheidary ebangathemostrecentfdaapproveddrugfortreatingebola AT marjanmoghadamnia ebangathemostrecentfdaapproveddrugfortreatingebola |